Drug intelligence / Profile preview

USM106

Development stage: Preclinical
Lead developer: Uscare Pharm
Modality: Hydrogel Systems → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems, Device-based Delivery → Drug Delivery Systems

Overview

USM106 is a discovery-stage biomaterial candidate being developed by Uscare Pharm. It is categorized within the company's 'Material Innovation' pipeline, which focuses on the development of novel substances for medical and regenerative applications. As of the latest pipeline updates, USM106 is in the early research and discovery phase. Specific details regarding its chemical composition, biological targets, or precise therapeutic indications beyond the broad category of biomaterials have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on USM106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on USM106.

Explore the full profile